Humuline Nph Cartridge (Insulin Human (Rdna))

Humuline NPH Cartridge is indicated for the treatment of diabetes mellitus where intermediate‑acting insulin is required. It is supplied in a cartridge compatible with reusable insulin pens, allowing precise dose adjustments.

• Type 1 diabetes mellitus as part of basal insulin therapy.
• Type 2 diabetes mellitus when basal insulin is needed in addition to oral agents.
• Adjunct to rapid‑acting insulin for a basal‑bolus regimen.
• Children and adolescents with type 1 diabetes who require basal insulin coverage.
• Adults requiring once‑ or twice‑daily basal insulin dosing to achieve target glycemic control.

• Insulin human (rDNA) in Humuline NPH Cartridge binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers autophosphorylation and downstream signaling through the PI3‑K/Akt pathway, promoting translocation of GLUT‑4 transporters to the cell membrane and enhancing glucose uptake. In the liver, it suppresses gluconeogenesis and glycogenolysis, leading to reduced endogenous glucose production. The NPH formulation provides a delayed onset and intermediate duration of action.

Adverse reactions reported with Humuline NPH Cartridge are generally consistent with those of intermediate‑acting insulin preparations.

Common

• Hypoglycemia, especially if meals are missed or dosing is excessive.
• Injection site reactions such as redness, swelling, or itching.
• Weight gain associated with improved glycemic control.
• Lipodystrophy at repeated injection sites.
• Transient visual disturbances during episodes of low blood sugar.

Serious

• Severe hypoglycemia leading to loss of consciousness or seizures.
• Allergic reactions including urticaria, angioedema, or anaphylaxis.
• Edema or heart failure exacerbation in susceptible patients.
• Hypersensitivity leading to serum sickness‑like reaction.

When prescribing or using Humuline NPH Cartridge, clinicians and patients should consider several safety precautions.

• Assess renal and hepatic function before initiating therapy, as impairment may alter insulin clearance.
• Adjust dose during periods of illness, stress, or changes in physical activity.
• Monitor blood glucose closely when starting, changing dose, or switching insulin types.
• Use caution in pregnant or breastfeeding individuals; benefits must outweigh potential risks.
• Educate patients on recognizing and treating hypoglycemia promptly.
• Review concomitant medications that may mask hypoglycemia symptoms.
• Store the cartridge at controlled room temperature and avoid freezing.

Humuline NPH Cartridge can interact with other medicines, affecting glucose control or insulin action.

Avoid

• Concurrent use of other insulin products without dose adjustment, which may cause severe hypoglycemia.
• Beta‑blockers that can mask hypoglycemia symptoms.
• High‑dose corticosteroids that markedly increase blood glucose levels.
• Monoamine oxidase inhibitors (MAOIs) that may interfere with carbohydrate metabolism.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that can potentiate hypoglycemia.
• Diuretics that may affect electrolyte balance and insulin sensitivity.
• ACE inhibitors or ARBs, which may enhance insulin sensitivity and require monitoring.
• Thiazide diuretics that can raise blood glucose, requiring closer monitoring.